MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma

You,Si-Hong; Wang,Xiang; Huang,Shu; Wang,Min; Ji,Guo-Zhong; Xia,Jin-Rong; Fan,Zhi-Ning

doi:10.3892/mmr.2012.1175

MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma

Authors:
- Si-Hong You
- Xiang Wang
- Shu Huang
- Min Wang
- Guo-Zhong Ji
- Jin-Rong Xia
- Zhi-Ning Fan
View Affiliations

Affiliations: Medical Center for Digestive Diseases, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, P.R. China, Department of Gastroenterology, ZhongDa Hospital, Southeast University, Nanjing 210009, P.R. China
Published online on: November 8, 2012 https://doi.org/10.3892/mmr.2012.1175
Pages: 347-351

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma (CCA) is a rare but devastating malignancy. Up to 90% of patients presenting with CCA have no identifiable risk factors. The base excision repair (BER) pathway has a principal role in the repair of mutations caused by oxidized or reduced bases. The MutY homolog (MUTYH, MYH) is one of the key proteins in the BER pathway, but the role of MYH in the tumorigenesis of CCA is largely unknown. In this study, we investigated the influence of MYH rs3219476 and rs3219472 polymorphisms on CCA incidence. MYH genotypes were detected using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. We found that for rs3219472, compared with subjects carrying the MYH G/G genotype, those with the A/A genotype had a 2.816-fold higher risk of CCA [odds ratio (OR)=2.816, 95% confidence interval (CI)=0.992-7.999, P=0.047). For rs3219476, compared with subjects carrying the MYH T/T genotype, those with the T/G genotype had a reduced risk of CCA (OR=0.359, 95% CI=0.17-0.758, P=0.006). Our findings suggest that since significantly increased CCA risk was found in individuals with a homozygous variant genotype for rs3219472, it may be a biomarker for screening individuals at high risk of developing the disease.

View Figures

View References

1	Isomoto H: Epigenetic alterations associated with cholangiocarcinoma (Review). Oncol Rep. 22:227–232. 2009.PubMed/NCBI
2	Petrowsky H and Hong JC: Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc. 41:4023–4035. 2009. View Article : Google Scholar : PubMed/NCBI
3	Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
4	Gatto M, Bragazzi MC, Semeraro R, et al: Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 42:253–260. 2010. View Article : Google Scholar : PubMed/NCBI
5	Shen FZ, Zhang BY, Feng YJ, et al: Current research in perineural invasion of cholangiocarcinoma. J Exp Clin Cancer Res. 29:242010. View Article : Google Scholar : PubMed/NCBI
6	Meza-Junco J, Montano-Loza AJ, Ma M, Wong W, Sawyer MB and Bain VG: Cholangiocarcinoma: has there been any progress? Can J Gastroenterol. 24:52–57. 2010.PubMed/NCBI
7	Ustundag Y and Bayraktar Y: Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol. 14:6458–6466. 2008. View Article : Google Scholar : PubMed/NCBI
8	Shields PG and Harris CC: Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol. 18:2309–2315. 2000.PubMed/NCBI
9	Galvan A, Ioannidis JP and Dragani TA: Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet. 26:132–141. 2010. View Article : Google Scholar : PubMed/NCBI
10	Martin SA, Hewish M, Lord CJ and Ashworth A: Genomic instability and the selection of treatments for cancer. J Pathol. 220:281–289. 2010.PubMed/NCBI
11	Jiang J, Zhang X, Yang H and Wang W: Polymorphisms of DNA repair genes: ADPRT, XRCC1, and XPD and cancer risk in genetic epidemiology. Methods Mol Biol. 471:305–333. 2009. View Article : Google Scholar : PubMed/NCBI
12	David SS, O’Shea VL and Kundu S: Base-excision repair of oxidative DNA damage. Nature. 447:941–950. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kasahara M, Osawa K, Yoshida K, et al: Association of MUTYH Gln324His and APEX1 Asp148Glu with colorectal cancer and smoking in a Japanese population. J Exp Clin Cancer Res. 27:492008. View Article : Google Scholar : PubMed/NCBI
14	Baudhuin LM, Roberts LR, Enders FT, et al: MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients. J Cancer Res Clin Oncol. 132:159–162. 2006. View Article : Google Scholar : PubMed/NCBI
15	Wang X, You SH, He W, et al: hOGG1 Ser326Cys polymorphisms and genetic susceptibility of cholangiocarcinomas. Journal of Medical Postgraduates. 23:1156–1159. 2010.(In Chinese).
16	You SH, Wang X, Huang S, Gao Y, Xia JR and Fan ZN: XRCC1 polymorphisms and genetic susceptibility of cholangiocarcinomas. Chinese Journal of Clinical Research. 23:1068–1072. 2010.(In Chinese).
17	Tsukino H, Hanaoka T, Otani T, et al: hOGG1 Ser326Cys polymorphism, interaction with environmental exposures, and gastric cancer risk in Japanese populations. Cancer Sci. 95:977–983. 2004. View Article : Google Scholar : PubMed/NCBI
18	Jones S, Emmerson P, Maynard J, et al: Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C->T:A mutations. Hum Mol Genet. 11:2961–2967. 2002. View Article : Google Scholar : PubMed/NCBI
19	Thyagarajan B, Lindgren B, Basu S, et al: Association between genetic variants in the base excision repair pathway and outcomes after hematopoietic cell transplantations. Biol Blood Marrow Transplant. 16:1084–1089. 2010. View Article : Google Scholar : PubMed/NCBI
20	Van Beers BE: Diagnosis of cholangiocarcinoma. HPB (Oxford). 10:87–93. 2008.
21	Sieber OM, Lipton L, Crabtree M, et al: Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med. 348:791–799. 2003. View Article : Google Scholar : PubMed/NCBI
22	Forsbring M, Vik ES, Dalhus B, et al: Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma. Carcinogenesis. 30:1147–1154. 2009. View Article : Google Scholar : PubMed/NCBI
23	Yang L, Zhou M, Zhu M, et al: Variation analysis of the MYH gene associated with sporadic colorectal cancer. Carcinogenesis, Teratogenesis and Mutagenesis. 21:435–438. 2009.(In Chinese).
24	Yang L, Zhu M, Chen SQ, et al: Research on MUTYH gene polymorphism associated with colorectal cancer. Shandong Medical Journal. 49:3–5. 2009.(In Chinese).